Clinical Presentation and Congenital Rubella Syndrome
The symptom complex developing in an infected fetus is termed congenital rubella syndrome (CRS). Its hallmark is the classic triad of developmental anomalies:
- Ocular involvement, most commonly presenting as cataracts leading to blindness.
- Severe sensorineural hearing loss or complete deafness.
- Various congenital heart defects.
- In addition to this triad, the pathogen exerts a destructive effect on the central nervous system. Combined with the loss of visual and auditory function, brain tissue damage inevitably leads to pronounced intellectual disability.
Pathogenesis of Fetal Injury
The development of severe anomalies is directly related to the timing of transplacental virus transmission. The most critical period is the first trimester of pregnancy. If infection occurs during this window, about 25% of infants are born with overt symptoms, and various developmental pathologies are recorded in up to 85%.
The teratogenic effect is mediated by three main factors:
- Inhibition of mitotic activity — normal embryonic cell division is disrupted.
- Tissue ischemia — caused by specific damage to placental blood vessels.
- Immunosuppressive action of the viral agent itself.
Additionally, the fetus suffers from direct cytopathogenic cell destruction and a colossal antigenic load on the still-forming immune system. At birth, high titers of maternal-derived specific antibodies are detected in the newborn. However, the infant's own adaptive immunity remains extremely unstable because its development proceeded under conditions of an immature immune system.
Late Complications: Progressive Rubella Panencephalitis
A unique feature of this infection is the pathogen's ability to persist in tissues long-term. This can lead to an optional slow virus infection. The most formidable complication is progressive rubella panencephalitis (PRPE).
The disease manifests in the second decade of life in individuals with the congenital form of the infection or those who contracted rubella in early childhood. The clinical picture of PRPE is characterized by steadily progressive mental and motor CNS deterioration. The prognosis is absolutely fatal.
Epidemiological nuance: patients with progressive rubella panencephalitis are completely non-contagious because the virus is absent from biological secretions.
Microbiological Diagnostics
Various clinical specimens are used for laboratory confirmation: blood, urine, and nasopharyngeal swabs. In severe cases or suspected PRPE, cerebrospinal fluid (CSF) and paired sera must be analyzed.
Main diagnostic approaches:
- Serological method — the foundational approach. Hemagglutination inhibition (HAI), neutralization, and ELISA are utilized. Key markers include specific IgM and IgG immunoglobulins, as well as IgG avidity index determination.
- Molecular method — detection of viral RNA using polymerase chain reaction (PCR).
- Virological method (viral culture isolation) is used extremely rarely due to high technical complexity.
The goal of diagnostics is to differentiate rubella from similar infections, determine the clinical form, and select the correct vaccination strategy.
Prevention and Vaccination Strategy
The primary goal of preventive measures is the elimination of circulating virus and total protection of pregnant women to prevent congenital rubella syndrome. Live attenuated strain vaccines are used for immunization.
According to standard vaccination schedules, the first dose is administered at 12–15 months, with a booster dose at 6 years.
Special attention in prevention is given to catch-up immunization strategies. This is necessary due to low herd immunity among adolescent girls. The strategy involves compulsory vaccination of all unvaccinated and uninfected children and adolescents under 18, as well as women aged 18–25. This approach drastically reduces the infection reservoir and minimizes the incidence of congenital anomalies.